Stiris Research Announces Site Initiated in Zucara’s Phase 1b Hypoglycemic Clamp Trial

London, ON — June 29, 2021 —

Stiris Research Inc. (“Stiris”), an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announces that they have initiated the site for the Phase 1b pharmacodynamic evaluation study of ZT-01 in Type 1 Diabetics (T1D) for sponsor Zucara Therapeutics Inc (“Zucara”).

Stiris is honoured to be working with Zucara on their clinical trial program for ZT-01.  This study will enroll approximately 25 T1D patients and will include hypoglycemic clamp procedures to define the safety and tolerability of this investigational product, as well as assess ZT-01’s effect on glucagon in this population.

“Activating a site and conducting a Phase 1 study in times of a pandemic is not an easy undertaking, but despite the circumstances, we are extremely pleased to have launched the CLAMP study. And thanks to the team’s commitment, we expect FPI any day now”, said Urszula Bartlomiejska, Project Manager, Stiris Research, Inc.

Stiris and Zucara recently completed a single and multiple ascending dose Phase 1 trial, in which ZT-01 was safe and well-tolerated.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.